BACKGROUND: Everolimus, a mammalian target of rapamycin (mTOR) inhibitor, has been used for various benign tumours associated with tuberous sclerosis complex. We assessed the efficacy and safety of two trough exposure concentrations of everolimus, 3-7 ng/mL (low exposure) and 9-15 ng/mL (high exposure), compared with placebo as adjunctive therapy for treatment-resistant focal-onset seizures in tuberous sclerosis complex. METHODS: In this phase 3, randomised, double-blind, placebo-controlled study, eligible patients aged 2-65 years with tuberous sclerosis complex and treatment-resistant seizures (≥16 in an 8-week baseline phase) receiving one to three concomitant antiepileptic drugs were recruited from 99 centres across 25 countries. Participants were randomly assigned (1:1:1), via permuted-block randomisation (block size of six) implemented by Interactive Response Technology software, to receive placebo, low-exposure everolimus, or high-exposure everolimus. Randomisation was stratified by age subgroup (<6 years, 6 to <12 years, 12 to <18 years, and ≥18 years). Patients, investigators, site personnel, and the sponsor's study team were masked to treatment allocation. The starting dose of everolimus depended on age, bodysurface area, and concomitant use of cytochrome 3A4/P-glycoprotein inducers. Dose adjustments were done to attain target trough ranges during a 6-week titration period, and as needed during a 12-week maintenance period of core phase. Patients or their caregivers recorded events in a seizure diary throughout the study. The primary endpoint was change from baseline in the frequency of seizures during the maintenance period, defined as response rate (the proportion of patients achieving ≥50% reduction in seizure frequency) and median percentage reduction in seizure frequency, in all randomised patients. This study is registered with ClinicalTrials.gov, number NCT01713946. FIND-INGS: Between July 3, 2013, and May 29, 2015, 366 patients were enrolled and randomly assigned to placebo (n=119), low-exposure everolimus, (n=117), or high-exposure everolimus (n=130). The response rate was 15·1% with placebo (95% CI 9.2-22.8; 18 patients) compared with 28.2% for low-exposure everolimus (95% CI 20.3-37.3; 33 patients; p=0.0077) and 40.0% for high-exposure everolimus (95% CI 31.5-49.0; 52 patients; p<0.0001). The median percentage reduction in seizure frequency was 14.9% (95% CI 0.1-21.7) with placebo versus 29.3% with low-exposure everolimus (95% CI 18.8-41.9; p=0.0028) and 39.6% with high-exposure everolimus (95% CI 35.0-48.7; p<0.0001). Grade 3 or 4 adverse events occurred in 13 (11%) patients in the placebo group, 21 (18%) in the low-exposure group, and 31 (24%) in the high-exposure group. Serious adverse events were reported in three (3%) patients who received placebo, 16 (14%) who received low-exposure everolimus, and 18 (14%) who received high-exposure everolimus. Adverse events led to treatment discontinuation in two (2%) patients in the placebo group versus six (5%) in the low-exposure group and four (3%) in the high-exposure group. INTERPRETATION: Adjunctive everolimus treatment significantly reduced seizure frequency with a tolerable safety profile compared with placebo in patients with tuberous sclerosis complex and treatment-resistant seizures.
Seizures in Tuberous Sclerosis: Mechanism-Based Interventions EXIST
TSC-related skin manifestations, cardiac rhabdomyomas, and pulmonary lymphangioleiomyomatosis (2) .
More than 80% of individuals with TSC develop epilepsy, usually in the first year of life. Half of all patients with tuberous sclerosis have epileptic spasms (constituting 7-25% of cases of West syndrome), and identification of the etiology in these cases is important because of a better response to vigabatrin. Overall, the epilepsy in about one-third of these individuals is drug resistant (3) .
Preclinical studies in tuberous sclerosis mouse models have demonstrated that mTOR inhibitors effectively prevent seizures (4) . In an open-label study, everolimus was tried for seizures, and subjects demonstrating initial benefit continued for a total of 4 years (3). Of the 20 participants who completed the initial study, 18 continued the extended treatment, and 78% of those completed the 4-year study. With the exception of one subject, all experienced more than 50% reduction of seizure frequency at 4 years. The treatment was also associated with some behavioral and quality of life improvements.
French et al. conducted a phase 3, randomized, doubleblind, placebo-controlled trial of everolimus in TSC. They included patients from age 2 to 65 years with medically intractable seizures from 99 centers in 25 countries. The patients were randomized to placebo, low exposure everolimus, or high exposure everolimus. Seizures were recorded in a seizure diary throughout the study. The authors recruited a total of 366 patients in 2 years. The results are summarized in the table. In brief, adjunctive treatment with everolimus significantly reduced seizure frequency and was generally considered tolerable. For safety reasons, patients younger than 2 years of age were not included in the study, but it would be interesting to see if this treatment can offer additional help for that age group. Of note, prior to enrollment, half the patients had failed 6 or more antiseizure medications with continuing median seizure frequency of approximately 38 per month. The degree of medical intractability of the recruited patient population makes the results even more impressive.
This study is very important because it not only offers an additional treatment to a subset of individuals with epilepsy but it also targets the actual molecular mechanism of seizures and other complications of TSC. Antiseizure medications work by reducing excitatory transmission in the central nervous system by such mechanisms as voltage-gated sodium channel blockade, glutamate receptor antagonism, and binding to synaptic vesicle proteins, among others. Other mechanisms include improving the inhibitory activity in the central nervous system by blocking the reuptake of GABA, inhibiting the enzymes that break down GABA, or modifying the response to GABA at its receptors. All of these mechanisms target the symptom, which is the excessive excitation that constitutes the seizure, and not on the actual pathophysiology of epilepsy. The study by French et al. may herald an era of targeting the very mechanism of seizures in specific epilepsy syndromes. Importantly, another recent study was specific to patients with Dravet syndrome (5), though it did not target the actual mechanism of Dravet, which is a sodium channel mutation.
In addition to TSC, activation of mTOR occurs also in other conditions associated with epilepsy. These include, among other "mTORopathies, " patients with focal cortical dysplasia IIb, and hemimegancephaly. Additionally, mTOR inhibitor treatment has proven beneficial in animal models of acquired temporal lobe epilepsy (6) and posttraumatic epilepsy (7) . Therefore, it would be interesting to see whether everolimus can reduce seizures in epilepsy syndromes other than TSC.
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